Bordetella pertussis
Bordetella pertussis infections continue to rise! In contrast to the time before and during the Covid pandemic, we are currently seeing alarmingly high numbers of respiratory infections caused by [...]
Diagnose Tuberculosis with IP-10
Ready to embrace the future of T-cell based Tuberculosis diagnosis? Three tubes, two choices: Rapid Test or ELISA. Complete the form below, and our team will reach out with more information about [...]
Obligation to report of chlamydia trachomatis serotypes L1- L3
Please note: The proof of chlamydia trachomatis serotypes L1- L3 is to be reported since September 2022 We would like to draw your attention to the crucial importance of differentiating between [...]
Increasing number of syphilis infections
Dramatic rise in syphilis infections: Warning of underestimated risk In recent years, the healthcare world has seen a concerning surge in syphilis infections. Between 2020 and 2022, reported [...]
Top priority at R-Biopharm: the IVDR
The EU has created a new legal framework for the quality and safety of in-vitro medical devices, namely the IVDR (Regulation on in-vitro diagnostic medical devices), which sets legally binding [...]
R-Biopharm announces quality products distribution agreement with Microbix
Mississauga, Canada and Darmstadt, Germany, 15th May 2020 – R-Biopharm AG and Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator, announces the appointment of R-Biopharm [...]